Extra-renal non-cerebral malignant rhabdoid tumor in children: does maintenance chemotherapy play a role in survival?
Diagnosis and Management of Multiple Myeloma: A Review.
Cowan AJ, Green DJ, Kwok M, Lee S, Coffey DG, Holmberg LA, Tuazon S, Gopal AK, Libby EN.
JAMA. 2022 Feb 1;327(5):464-477. doi: 10.1001/jama.2022.0003.
Chemotherapy Maintenance.
Kasi PM, Grothey A.
Cancer J. 2016 May-Jun;22(3):199-204. doi: 10.1097/PPO.0000000000000195.
Maintenance Therapy in Acute Myeloid Leukemia.
Sabakhtarishvili G, Ansari A, Tabbara IA.
Am J Clin Oncol. 2025 Jan 1;48(1):38-43. doi: 10.1097/COC.0000000000001140. Epub 2024 Sep 6.
The Role of Maintenance Strategies in Metastatic Colorectal Cancer: A Systematic Review and Network Meta-analysis of Randomized Clinical Trials.
Sonbol MB, Mountjoy LJ, Firwana B, Liu AJ, Almader-Douglas D, Mody K, Hubbard J, Borad M, Ahn DH, Murad MH, Bekaii-Saab T.
JAMA Oncol. 2020 Mar 1;6(3):e194489. doi: 10.1001/jamaoncol.2019.4489. Epub 2020 Mar 12.
Progression-free survival and safety at 3.5years of follow-up: results from the randomised phase 3 PRIMA/ENGOT-OV26/GOG-3012 trial of niraparib maintenance treatment in patients with newly diagnosed ovarian cancer.
González-Martín A, Pothuri B, Vergote I, Graybill W, Lorusso D, McCormick CC, Freyer G, Backes F, Heitz F, Redondo A, Moore RG, Vulsteke C, O'Cearbhaill RE, Malinowska IA, Shtessel L, Compton N, Mirza MR, Monk BJ.
Eur J Cancer. 2023 Aug;189:112908. doi: 10.1016/j.ejca.2023.04.024. Epub 2023 May 3.
How I use maintenance therapy in acute myeloid leukemia.
Roboz GJ, Canaani J.
Blood. 2025 Mar 20;145(12):1273-1281. doi: 10.1182/blood.2024024010.
Vinorelbine and continuous low-dose cyclophosphamide as maintenance chemotherapy in patients with high-risk rhabdomyosarcoma (RMS 2005): a multicentre, open-label, randomised, phase 3 trial.
Bisogno G, De Salvo GL, Bergeron C, Gallego Melcón S, Merks JH, Kelsey A, Martelli H, Minard-Colin V, Orbach D, Glosli H, Chisholm J, Casanova M, Zanetti I, Devalck C, Ben-Arush M, Mudry P, Ferman S, Jenney M, Ferrari A; European paediatric Soft tissue sarcoma Study Group.
Lancet Oncol. 2019 Nov;20(11):1566-1575. doi: 10.1016/S1470-2045(19)30617-5. Epub 2019 Sep 24.
Long-term follow-up of efficacy and safety of selinexor maintenance treatment in patients with TP53wt advanced or recurrent endometrial cancer: A subgroup analysis of the ENGOT-EN5/GOG-3055/SIENDO study.
Makker V, Perez-Fidalgo JA, Valabrega G, Hamilton E, Van Gorp T, Sehouli J, Regináčová K, Richardson DL, Perri T, Oza AM, Miller DS, Alía EMG, De Giorgi U, Henry S, Spitz DL, Wimberger P, Bednaříková M, Chon HS, Martínez-Garcia J, Pisano C, Berek JS, Romero I, Scambia G, Fariñas-Madrid L, Buscema J, Schochter F, Li K, Kalyanapu P, Walker CJ, Vergote I.
Gynecol Oncol. 2024 Jun;185:202-211. doi: 10.1016/j.ygyno.2024.05.016. Epub 2024 Jun 3.
Anticancer maintenance chemotherapy prolonged prognosis of metastatic urothelial carcinoma patients: A single institute retrospective study using propensity score matching.
Yamamoto A, Kawashima A, Uemura T, Yamamichi G, Tomiyama E, Koh Y, Matsushita M, Kato T, Hatano K, Uemura M, Imamura R, Nonomura N.
Int J Urol. 2022 Nov;29(11):1294-1303. doi: 10.1111/iju.14987. Epub 2022 Aug 24.
Outcome of maintenance systemic chemotherapy with drug-free interval for metastatic urothelial carcinoma.
Abe T, Minami K, Harabayashi T, Sazawa A, Chiba H, Kikuchi H, Miyata H, Matsumoto R, Osawa T, Maruyama S, Ishizaki J, Mochizuki T, Chiba S, Akino T, Murakumo M, Miyajima N, Tsuchiya K, Murai S, Shinohara N.
Jpn J Clin Oncol. 2019 Oct 1;49(10):965-971. doi: 10.1093/jjco/hyz084.
